**6. Conclusion**

AS as molecular target for drug development will be important for the treatment of a wide variety of diseases associated with deficiency of NO production, and also could transform *Bj*-PROs or their synthetic analogous into blockbuster medicine, as happened in the 80s with Captopril [90, 91]. The properties of *Bj*-PROs enhancing AS activity [14, 17], provides a pre‐ cise pharmacological tool for controlling pathophysiological mechanisms with advantages of uncontrolled application of exogenous L-arginine or NO donors [92]. For instance, the ef‐ fect of exogenous NO donors is not subject to physiological control, thus being more suscep‐ tible of generating undesired ROS [93, 94]. For all these reasons, keeping NO production in a safe level, so that a deleterious threshold would not be reached, is of particular interest. In this way, *Bj*-PROs should serve as structural models for the development of therapeutic agents for the treatment of various diseases related to NO deficiency, as cause or effect, as well AS deficiency.

Chemical properties of *Bj*-PROs make these peptides even more attractive potential lead compounds for drug development. For instance, *Bj*-PRO-10c is able to penetrate cells, where it remains as an intact molecule for hours [14]. Moreover, *Bj*-PROs contain a notable high proline content [13], which gives them some resistance to hydrolysis by aminopeptidases, carboxypeptidases and endopeptidases [95]. Nevertheless, cyclodextrins or nanocompounds could provide carriers for *Bj*-PROs, since drug release could be controlled in accordance with therapeutic propose [96, 97].
